Fundraising FoxBioBrit — 2021 Investments
2 investments dated 2021 · listed companies and verified rows first · show all
Amplo Biotechnology develops adeno-associated virus (AAV) gene therapies for genetic diseases of the neuromuscular junction, targeting rare and ultra-rare patient populations such as those with Congenital Myasthenic Syndromes.
BiotechHealthtechPompano Beach, US
Al Hawkins(President / Program Director)Jean Kim(Director)Paul Hawkins(Executive Officer, Director)Terry Vance(Director)Matthew Pauls(Director)Patricio Sepulveda(Executive Officer, Director)in
Persephone develops a synbiotic supplement for infants that combines probiotics (keystone Bifidobacterium strains) with prebiotics found in human breast milk to replenish gut bacteria linked to digestion, immunity, and development.
BiotechConsumerDigital HealthFemTechHealthtechSan Diego, US
Stephen Van Dien(CTO)inStephanie Culler(CEO)in
Co-investorsFirst Bight VenturesPropel Bio PartnersFifty YearsHemi Ventures, LlcOcampo CapitalPioneer+13 more
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.